JO3380B1 - مشابهات ابيلين اصطناعية لعلاج قصور القلب - Google Patents

مشابهات ابيلين اصطناعية لعلاج قصور القلب

Info

Publication number
JO3380B1
JO3380B1 JOP/2013/0027A JOP20130027A JO3380B1 JO 3380 B1 JO3380 B1 JO 3380B1 JO P20130027 A JOP20130027 A JO P20130027A JO 3380 B1 JO3380 B1 JO 3380B1
Authority
JO
Jordan
Prior art keywords
heart failure
polypeptides
synthetic
abilin
analogues
Prior art date
Application number
JOP/2013/0027A
Other languages
English (en)
Inventor
Golosov Andrei
Thomas Parker David
Zecri Frédéric
Grosche Philipp
Yasoshima Kayo
Hu Qi-Ying
Imase Hidetomo
Zhao Hongjuan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3380(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3380B1 publication Critical patent/JO3380B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A61M16/0066—Blowers or centrifugal pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/201—Controlled valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)

Abstract

يقدم الإختراع عديد البيبتيد التخليقي من الصيغة I': I’ أو أميد، إستر أو ملح منه، حيث تم تحديدX1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 و X13 هنا. عديدات البيبتيد هي عبارة عن مناهضات لمستقبل APJ. يتعلق الإختراع أيضا بطريقة لصناعة عديد البيبتيد الخاص بالإختراع، وإستخداماته العلاجية مثل العلاج أو الوقاية من فشل القلب الحاد (ADHF)، فشل القلب المزمن، سرعة ضربات القلب البطيني، تصلب الشرايين، إرتفاع ضغط الدم، أمراض فشل القلب والأوعية، إعتلال عضلة القلب، تليف القلب، عدم إنتظام ضربات القلب، مرض السكري (ويتضمن سكر الحمل)، السمنة، مرض الشريان الطرفي، حوادث الأوعية الدماغية، النوبات الإقفارية المؤقتة، إصابات المخ الإصطدامية، تصلب الشرايين الجانبي الضموري، إصابات الحرق (ويتضمن حروق الشمس) و تسمم الحمل. يقدم الإختراع الحالي أيضا تركيب من العوامل النشطة فارماكولوجيا وتركيب صيدلي.
JOP/2013/0027A 2012-01-27 2013-01-24 مشابهات ابيلين اصطناعية لعلاج قصور القلب JO3380B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591557P 2012-01-27 2012-01-27
US201261717760P 2012-10-24 2012-10-24
US201261731697P 2012-11-30 2012-11-30

Publications (1)

Publication Number Publication Date
JO3380B1 true JO3380B1 (ar) 2019-03-13

Family

ID=47997598

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0027A JO3380B1 (ar) 2012-01-27 2013-01-24 مشابهات ابيلين اصطناعية لعلاج قصور القلب

Country Status (42)

Country Link
US (3) US8673848B2 (ar)
EP (1) EP2807183B1 (ar)
JP (2) JP6313222B2 (ar)
KR (2) KR20200003229A (ar)
CN (1) CN104220452B (ar)
AP (1) AP2014007846A0 (ar)
AR (1) AR089808A1 (ar)
AU (1) AU2013213265C1 (ar)
BR (1) BR112014018306A8 (ar)
CA (1) CA2862240A1 (ar)
CL (1) CL2014001994A1 (ar)
CO (1) CO7020879A2 (ar)
CR (1) CR20140364A (ar)
CU (1) CU24266B1 (ar)
CY (1) CY1120239T1 (ar)
DK (1) DK2807183T3 (ar)
EA (1) EA027853B1 (ar)
EC (1) ECSP14016014A (ar)
ES (1) ES2670832T3 (ar)
GT (1) GT201400166A (ar)
HR (1) HRP20180806T1 (ar)
HU (1) HUE039137T2 (ar)
IL (1) IL233792B (ar)
JO (1) JO3380B1 (ar)
LT (1) LT2807183T (ar)
MX (1) MX351569B (ar)
MY (1) MY172268A (ar)
NZ (1) NZ627772A (ar)
PE (1) PE20142194A1 (ar)
PH (1) PH12014501701A1 (ar)
PL (1) PL2807183T3 (ar)
PT (1) PT2807183T (ar)
RS (1) RS57200B1 (ar)
SG (1) SG11201404369PA (ar)
SI (1) SI2807183T1 (ar)
TN (1) TN2014000318A1 (ar)
TR (1) TR201807309T4 (ar)
TW (1) TWI576356B (ar)
UA (1) UA116196C2 (ar)
UY (1) UY34593A (ar)
WO (1) WO2013111110A2 (ar)
ZA (1) ZA201405400B (ar)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014083505A1 (en) * 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins
US20160067347A1 (en) * 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
JP6525951B2 (ja) 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アペリン融合タンパク質およびその使用
US9908919B2 (en) * 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
CN105764530B (zh) 2013-11-26 2019-09-13 诺华股份有限公司 用于对酮修饰的多肽类进行肟缀合的方法
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
SG11201605195RA (en) * 2014-03-25 2016-10-28 Lanthiopep Bv Cyclic apelin analogs
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
ES2792598T3 (es) 2014-05-23 2020-11-11 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
CN112851790A (zh) 2014-06-23 2021-05-28 诺华股份有限公司 位点特异性蛋白质修饰
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
WO2016116842A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
ES2805743T3 (es) * 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
CA2985542C (en) 2015-05-20 2023-10-10 Amgen Inc. Triazole agonists of the apj receptor
EP3416688B1 (en) 2016-02-15 2022-08-17 INSERM - Institut National de la Santé et de la Recherche Médicale Apelin for use in the treatment of post-operative cognitive dysfunction
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CN121081388A (zh) 2016-10-19 2025-12-09 阿维夫公司 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP3837276A4 (en) 2018-08-16 2022-05-18 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN112007027B (zh) * 2020-09-14 2022-07-15 长春金赛药业有限责任公司 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用
CN119101143A (zh) * 2023-05-31 2024-12-10 浙江大学 一种G蛋白偏向的apelin-13多肽突变体及应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759804A (en) 1992-11-17 1998-06-02 Icos Corporation Isolated nucleic acid encoding seven transmembrane receptors
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
AU5759399A (en) 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
CA2346064A1 (en) 1998-10-05 2000-04-13 Takeda Chemical Industries, Ltd. Method for removing n-terminal methionine
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
KR20020081466A (ko) 2000-03-23 2002-10-26 다케다 야쿠힌 고교 가부시키가이샤 펩티드 유도체
WO2001090123A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
AU2002367839A1 (en) 2001-07-16 2003-11-17 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
WO2003063892A1 (en) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US20050152836A1 (en) 2003-05-22 2005-07-14 Euan Ashley Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
EP1768951A4 (en) 2004-06-17 2011-06-15 Musc Found For Res Dev NON-NATURAL AMINO ACIDS
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
US20110097710A1 (en) 2004-10-26 2011-04-28 Macrae Calum A Methods for detecting atrial fibrillation and related conditions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
WO2007123233A1 (ja) 2006-04-25 2007-11-01 Kyushu University, National University Corporation 動脈硬化性疾患関連遺伝子、およびその利用
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP2010538981A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独でまたはペプチドＧｌｙ−Ａｒｇ−Ｇｌｙ−Ａｓｐ−Ａｓｎ−Ｐｒｏ−ＯＨと組み合わせて用いる、治療剤としてのペプチドＨｉｓ−Ｓｅｒ−Ｌｅｕ−Ｇｌｙ−Ｌｙｓ−Ｔｒｐ−Ｌｅｕ−Ｇｌｙ−Ｈｉｓ−Ｐｒｏ−Ａｓｐ−Ｌｙｓ−Ｐｈｅの使用
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CA2742528A1 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
US9908919B2 (en) 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure

Also Published As

Publication number Publication date
MX2014009085A (es) 2014-08-27
EA027853B1 (ru) 2017-09-29
US20130196899A1 (en) 2013-08-01
PE20142194A1 (es) 2014-12-21
JP6313222B2 (ja) 2018-04-18
HRP20180806T1 (hr) 2018-06-29
HUE039137T2 (hu) 2018-12-28
AR089808A1 (es) 2014-09-17
HK1200470A1 (en) 2015-08-07
CA2862240A1 (en) 2013-08-01
RS57200B1 (sr) 2018-07-31
PH12014501701A1 (en) 2014-10-13
LT2807183T (lt) 2018-05-10
ZA201405400B (en) 2016-08-31
CY1120239T1 (el) 2019-07-10
BR112014018306A8 (pt) 2017-07-11
AU2013213265C1 (en) 2016-09-29
CU20140097A7 (es) 2015-03-30
EA201491433A1 (ru) 2014-12-30
US8673848B2 (en) 2014-03-18
EP2807183B1 (en) 2018-02-28
US20150252076A1 (en) 2015-09-10
ECSP14016014A (es) 2015-11-30
MX351569B (es) 2017-10-19
GT201400166A (es) 2015-10-15
AU2013213265A1 (en) 2014-09-18
TR201807309T4 (tr) 2018-06-21
MY172268A (en) 2019-11-20
WO2013111110A3 (en) 2013-10-31
US9982017B2 (en) 2018-05-29
JP6595553B2 (ja) 2019-10-23
CL2014001994A1 (es) 2014-11-03
JP2015506370A (ja) 2015-03-02
US9067971B2 (en) 2015-06-30
IL233792B (en) 2018-04-30
PL2807183T3 (pl) 2018-08-31
TWI576356B (zh) 2017-04-01
IL233792A0 (en) 2014-09-30
UA116196C2 (uk) 2018-02-26
CU24266B1 (es) 2017-07-04
ES2670832T3 (es) 2018-06-01
AU2013213265B2 (en) 2016-05-26
TN2014000318A1 (en) 2015-12-21
DK2807183T3 (en) 2018-06-06
US20140142022A1 (en) 2014-05-22
SG11201404369PA (en) 2014-08-28
UY34593A (es) 2013-09-02
TW201335190A (zh) 2013-09-01
EP2807183A2 (en) 2014-12-03
SI2807183T1 (en) 2018-05-31
CN104220452A (zh) 2014-12-17
KR102068370B1 (ko) 2020-01-21
BR112014018306A2 (ar) 2017-06-20
JP2018048157A (ja) 2018-03-29
AP2014007846A0 (en) 2014-08-31
KR20140117603A (ko) 2014-10-07
NZ627772A (en) 2015-11-27
CR20140364A (es) 2014-11-17
CO7020879A2 (es) 2014-08-11
PT2807183T (pt) 2018-05-29
CN104220452B (zh) 2018-01-26
KR20200003229A (ko) 2020-01-08
WO2013111110A2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
JO3380B1 (ar) مشابهات ابيلين اصطناعية لعلاج قصور القلب
PH12016500103A1 (en) Bioconjugates of synthetic apelin polypeptides
PH12016500104A1 (en) Cyclic polypeptides for the treatment of heart failure
UY35144A (es) Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP2018048157A5 (ar)
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
MX394763B (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
PH12017501112A1 (en) Synthetic apelin fatty acid conjugates with improved half-life
EA201391339A1 (ru) Применение антагонистов рецептора аденозина aдля лечения сердечной недостаточности и аритмии у пациентов после инфаркта миокарда
WO2013048116A3 (ko) 에리스로포이에틴-유래 펩타이드 및 그 용도
TN2016000029A1 (en) Bioconjugates of synthetic apelin polypeptides
JP2018507187A5 (ar)
CY1116088T1 (el) Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων
AR096980A1 (es) Polipéptidos cíclicos para el tratamiento de insuficiencia cardiaca
Aizawa et al. Atrial Fibrillation Revisited—With a Special Reference to Primary Prevention—
TH1801005246A (th) ลิรากลูไทด์ในสภาวะหัวใจและหลอดเลือด